Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study

BACKGROUND: Concurrent chemo-radiotherapy remains the standard treatment in unresectable stage III non-small-cell lung cancer (NSCLC) patients. Several studies have shown a potential value of concurrent epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) with thoracic radiotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: ZHU, Lucheng, Zou, Changlin, Zhang, Zhanchun, Wang, Jianfang, Yang, Li, Rao, Chuangzhou, Yang, Zhiping, Liang, Jiafeng, Xia, Bing, Shenglin, M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103745/
https://www.ncbi.nlm.nih.gov/pubmed/33962566
http://dx.doi.org/10.1186/s12885-021-08266-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103745/
https://www.ncbi.nlm.nih.gov/pubmed/33962566
http://dx.doi.org/10.1186/s12885-021-08266-w

Ejemplares similares